ClinicalTrials.gg
Active, not recruitingNCT03127709Updated May 7, 2026

A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis

An observational study in Histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
13
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Histiocytosis with a site in United States — 2 open to participants now, 5 under way, none of them phase 3. Histiocytosis · United States.

Started
2017
the only one that year
Observational
3 of 14
1 open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
Memorial Sloan Kettering Cancer Center

Among the 14 studies in Histiocytosis with a site in United States, this one is the only one that started in 2017, is one of 3 observational ones, and was the 12th registered.

Histiocytosis

25 studies on the registry are indexed under Histiocytosis; 8 are open to participants now.

Browse Histiocytosis studies →

Open to participants now

2 of the 14 studies in Histiocytosis with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Histiocytosis studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Histiocytosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to try to understand how histopcytosis can cause symptoms or problems in the brain. The tests being done in the study will look at memory and thinking as well as brain function via MRI scan.

03

Conditions studied

  • Histiocytosis

Browse trials for

Keywords

  • 17-199
  • histiocytosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will have a diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 years.
  • Fluency in English
  • Diagnosis of a histiocytic disorder as determined, in the opinion of the study PI, by a corroborating constellation of histopathology, clinical, and/or radiologic findings.
  • Will undergo Standard of Care MRI.

Exclusion criteria

Exclusion Criteria:

  • Known intracranial involvement of histiocytosis (including dura, leptomeninges and brain parenchyma)
  • Prior stroke or intracranial hemorrhage
  • Other (non-histiocytic) intracranial neoplasm or neurological disorder deemed by the PI or Co-PI to confound neuroimaging studies (e.g., demyelinating disease)
  • Existing diagnosis of a psychiatric disorder or untreated mood disturbance
  • Existing diagnosis of a neurodegenerative disease, such as Alzheimer's disease
  • Chronic or daily excessive alcohol consumption as determined by the PI.
  • History of chronic use of , defined as continuous treatment for six months or longer at any time in the past
  • History of severe claustrophobia or other to patient SOC brain MRI
  • Prior intravenous cytarabine or cladribine
  • Other current or prior treatments (e.g., high-dose chemotherapy for a different cancer) deemed by the PI or Co-PI to confound imaging studies or cognitive performance
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
13 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants with a histiocytic disorder diagnosis

    Participants will have a histiocytic disorder as determined by a corroborating constellation of histopathology, clinical, and/or radiologic findings.

    Behavioral: Trail Making Test, Parts A & B · Behavioral: Brief Test of Attention · Behavioral: Symbol Span · Behavioral: Controlled Oral Word Association Test · Behavioral: The Hopkins Verbal Learning Test-Revised · Behavioral: Brief Visuospatial Memory Test-Revised · Behavioral: Hospital Anxiety and Depression Scale · Behavioral: McGill Quality of Life Scale · Diagnostic Test: MR Brain Imaging · Diagnostic Test: Resting state functional MRI · Behavioral: Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)

Interventions

  • BehavioralTrail Making Test, Parts A & B

    Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.

  • BehavioralBrief Test of Attention

    Assesses auditory working memory

    Also known as: BTA

  • BehavioralSymbol Span

    Assesses visual working memory

    Also known as: WMS-IV

  • BehavioralControlled Oral Word Association Test

    The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).

    Also known as: COWA

  • BehavioralThe Hopkins Verbal Learning Test-Revised

    HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.

    Also known as: HVLT-R

  • BehavioralBrief Visuospatial Memory Test-Revised

    The BVMT-R is a test of visuospatial learning and memory.

    Also known as: BVMT-R

  • BehavioralHospital Anxiety and Depression Scale

    The HADS is a brief assessment validated in many cancer populations.

    Also known as: HADS

  • BehavioralMcGill Quality of Life Scale

    This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.

    Also known as: McGill QOL

  • Diagnostic testMR Brain Imaging

    Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.

  • Diagnostic testResting state functional MRI

    Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2\*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.

    Also known as: rsFMRI

  • BehavioralFunctional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)

    This is a validated 37-item QOL instrument for cancer patients with cognitive complaints. The measures consist of FACT-Cog total, perceived cognitive impairments, perceived cognitive abilities, and impact on quality of life.

06

What researchers measure

Primary outcomes

  1. neurocognitive function

    Neurocognitive tests will yield raw scores that are converted to z-scores, normalized for participant's age, sex and educational level.The proportion of participants demonstrating cognitive impairment (as defined by 2 or more z-scores less than -1.5) will be summarized. Also, the proportion of participants with impairment (z \< -1.5) for each cognitive test will be summarized. In this way the cognitive assessment yields a dichotomous outcome of impaired versus not impaired for each participant but also allow for more granular assessment of impairment in specific cognitive domains.

    Time frame: 1 year

  2. quality of life

    questionnaires will yield raw scores (total score for HADS and McGill QOL, as well as anxiety and depression subscores for the HADS). QOL scores will be analyzed as raw scores. Cognitive test scores will be transformed into z-sores (based on score distributions from established normative samples with a mean of 0 and standard deviation of 1) to define the presence/severity of cognitive dysfunction. Scores will be normalized for age, sex and education.

    Time frame: 1 year

  3. comparing of grey matter volume

    In a whole-brain analysis, first, cortical thickness will be compared between participants and controls and regions of statistically significant grey matter loss will be identified. This is done computionally with a whole-brain, vertex-by-vertex approach, as stated above. Also, as stated above (Section 7), statistical significance thresholding is at p\<0.001, correcting for multiple comparisons using the False Discovery Rate (FDR) method and clustering thresholds, methods used in various high-throughput contexts, including MRI analysis.

    Time frame: 1 year

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2017 (actual). Primary completion is estimated for Apr 2027, 120 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2017
First posted
Apr 25, 2017
StartActual
Apr 7, 2017
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03127709
Responsible party
Sponsor
First posted
Apr 25, 2017
Start date
Apr 7, 2017
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
May 7, 2026

Study contacts

Eli Diamond, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion